Metabolism of Beclomethasone Dipropionate by Cytochrome P450 3A Enzymes
- 1 May 2013
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 345 (2) , 308-316
Abstract
Inhaled glucocorticoids, such as beclomethasone dipropionate (BDP), are the mainstay treatment of asthma. However, ∼30% of patients exhibit little to no benefit from treatment. It has been postulated that glucocorticoid resistance, or insensitivity, is attributable to individual differences in glucocorticoid receptor-mediated processes. It is possible that variations in cytochrome P450 3A enzyme-mediated metabolism of BDP may contribute to this phenomenon. This hypothesis was explored by evaluating the contributions of CYP3A4, 3A5, 3A7, and esterase enzymes in the metabolism of BDP in vitro and relating metabolism to changes in CYP3A enzyme mRNA expression via the glucocorticoid receptor in lung and liver cells. CYP3A4 and CYP3A5 metabolized BDP via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; CYP3A7 did not metabolize BDP. A new metabolite [M6], formed by the combined action of esterases and CYP3A4 hydroxylation, was also characterized. To validate the results observed using microsomes and recombinant enzymes, studies were also conducted using A549 lung and DPX2 liver cells. Both liver and lung cells produced esterase-dependent metabolites [M1–M3], with [M1] correlating with CYP3A5 mRNA induction in A549 cells. Liver cells produced both hydroxylated and dehydrogenated metabolites [M4, M5, and M6], but lung cells produced only the dehydrogenated metabolite [M5]. These studies show that CYP3A4 and CYP3A5 metabolize BDP to inactive metabolites and suggest that differences in the expression or function of these enzymes in the lung and/or liver could influence BDP disposition in humans.Keywords
This publication has 37 references indexed in Scilit:
- CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid controlDrug Metabolism and Drug Interactions, 2013
- Nanosilver Particle Effects on Drug Metabolism In VitroDrug Metabolism and Disposition, 2010
- The Inhaled Glucocorticoid Fluticasone Propionate Efficiently Inactivates Cytochrome P450 3A5, a Predominant Lung P450 EnzymeChemical Research in Toxicology, 2010
- Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoidsDrug Metabolism Reviews, 2010
- Profiling gene expression of whole cytochrome P450 superfamily in human bronchial and peripheral lung tissues: Differential expression in non-small cell lung cancersBiochimie, 2010
- BIOTRANSFORMATION OF FLUTICASONE: IN VITRO CHARACTERIZATIONDrug Metabolism and Disposition, 2006
- Mometasone furoate degradation and metabolism in human biological fluids and tissuesBiopharmaceutics & Drug Disposition, 2003
- Regulation of CYP3A5 by Glucocorticoids and Cigarette Smoke in Human Lung-Derived CellsThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Deposition and Effects of Inhaled CorticosteroidsClinical Pharmacokinetics, 2003
- Beclomethasone Dipropionate A Reappraisal of its Pharmacodynamic Properties and Therapeutic Efficacy After a Decade of Use in Asthma and RhinitisDrugs, 1984